Literature DB >> 2738675

Evaluation of ventricular function with first-pass iridium-191m radionuclide angiocardiography.

C Hellman1, N Zafrir, A Shimoni, D Issachar, J Trumper, S Abrashkin, E Lubin.   

Abstract

Iridium-191m would appear to be a highly useful agent for first-pass radionuclide angiocardiography (FPNA), with its very short half-life (4.96 sec), dual photopeaks (65 and 129 keV), and high injectable activity levels (greater than 100 mc). In order to compare 191mIr FPNA to current methods used to define cardiac function, 20 patients referred for cardiac catheterization were studied. Count rate data, right ventricular (RV), and left ventricular ejection fraction (LVEF), LV and diastolic volume (EDV), and end diastolic long axis (AXIS) were evaluated. Count rate data using 191mIr FPNA was consistently better than similar data obtained by 99mTc FPNA. There were acceptable correlations between 191mIr and 99mTc FPNA RVEF (r = 0.848), 191mIr FPNA and contrast angiography LVEF (r = 0.944), LVEDV (r = 0.917), and LV AXIS (r = 0.866). The data thus suggests that 191mIr FPNA has great potential in the evaluation of cardiac function.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2738675

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  3 in total

Review 1.  The continuing important role of radionuclide generator systems for nuclear medicine.

Authors:  F F Knapp; S Mirzadeh
Journal:  Eur J Nucl Med       Date:  1994-10

2.  The use of iridium-191m for pulmonary blood flow imaging.

Authors:  M Bocher; D Issachar; M Zabari; H Karger; R Chisin
Journal:  Eur J Nucl Med       Date:  1994-05

3.  Correlation between ST elevation and Q waves on the predischarge electrocardiogram and the extent and location of MIBI perfusion defects in anterior myocardial infarction.

Authors:  Barak Zafrir; Nili Zafrir; Tuvia Ben Gal; Yehuda Adler; Zaza Iakobishvili; M Atiar Rahman; Yochai Birnbaum
Journal:  Ann Noninvasive Electrocardiol       Date:  2004-04       Impact factor: 1.468

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.